Human prostate cancer (PC) overexpresses the gastrin-releasing peptide receptor (GRPR). Radiolabelled GRPR-targeting analogues of bombesin (BN) have successfully been introduced as potential tracers for visualization and treatment of GRPRoverexpressing tumours. A previous study showed GRPR-mediated binding of radiolabelled BN analogues in androgen-dependent but not in androgen-independent xenografts representing the more advanced stages of PC. We have further investigated the effect of androgen modulation on GRPR-expression in three androgen-dependent human PC-bearing xenografts: PC295, PC310 and PC82 using the androgenindependent PC3-model as a reference. Effects of androgen regulation on GRPR expression were initially studied on tumours obtained from our biorepository of 
Introduction
Prostate cancer (PC) is the third leading cause of cancer-related deaths and the most frequently diagnosed cancer in men in Western countries 1 . PC will increase to be a major health problem due to the aging of people in the Western world and currently developed screening strategies that result in diagnosis at more early stage of disease. In case of metastasised late stage PC standard therapy exists of hormone deprivation which is initially effective in the majority of patients 2 . Eventually however PC patients will relapse due to progression of PC towards hormone-independent growth of the tumour.
Unfortunately, advanced PC responds poorly to chemotherapeutic agents of which taxane-based treatments are nowadays considered the standard second-line treatment of hormone-resistant PC 3, 4 . Finally, most patients with metastasised PC will die of progressive, hormone-independent disease. Treatment and imaging of PC demands for new concepts, a potential strategy lies in targeting tumour-specific receptors. It could improve staging of PC determining locality of disease at time of diagnosis which is required to define treatment decisions.
It has been shown that prostate tumours overexpress the gastrin-releasing peptide receptor (GRPR) [5] [6] [7] [8] [9] . Overexpression of these receptors in PC is restricted to the malignant cells, as normal and hyperplastic prostate tissue were shown to be GRPRnegative 5 . The GRPR is a member of the bombesin (BN) receptor family consisting of four known receptor subtypes. Three of them the neuromedin B (NMB) receptor (BB 1 ), GRPR (BB 2 ) and BN receptor subtype 3 (BRS-3 or BB 3 ), are mammalian receptors, whereas the fourth subtype (BB 4 ) is found only in amphibians [9] [10] [11] [12] [13] . BN-like receptors, such as NMB, BB 2 and BB 3 are involved in the regulation of a large number of biological processes in the gut and central nervous system 14 and mediate their action by binding to their BN receptor subtypes. BN analogues are attractive peptides to be used to target the GRPR. Its use has been proposed for chemotherapy using cytotoxic BN analogues and for nuclear interventions employing radiolabelled BN analogues to perform peptide-receptor scintigraphy and radionuclide therapy (PRRT) 5 .
In a previous study we evaluated the expression of GRPRs in different stages of tumour development using a panel of 12 xenograft models from 9 different patients representing the various stages of human PC ranging from androgen-dependent to androgen-independent disease 15, 16 . We found GRPR-mediated binding of radiolabelled BN analogues only in androgen-dependent but not in androgen-independent xenografts representing the more advanced stages of prostate tumour development 17 . Also, in a pilot study, GRPR-expression of an androgen-dependent xenograft showed reduced uptake after androgen ablation treatment, suggesting that GRPR-expression may be influenced by androgens and may be related to the progressive state of PC.
Since the majority of patients are treated with hormonal therapy during the course of their disease, it is highly relevant to study the impact of hormonal ablation treatment on GRPR expression in order to reveal whether such patients could still be eligible to GRPR targeted modalities. Therefore, the purpose of the present study was to further investigate androgen regulation of the GRPR in three androgen-dependent human PC xenograft models PC82, PC295 and PC310 that represent the early androgen-responsive state of human PC 18 . We hypothesized that if GRPR is androgen regulated, the expression is reduced by androgen ablation in androgen-dependent xenograft-bearing mice, and should be reversed by restoring the hormonal status of the animals. This experimental design allows to elucidate the direct effects of hormonal changes on GRPR expression in relevant models for human PC. Since resupplementation of patients with testosterone is not likely to be applicable in PC patients, the present study set-up is merely experimental in nature and less intended to mimic the clinical setting. Knowledge about the background of hormonal regulation of the GRPR will provide crucial information for the clinical use of GRPR-based technologies. It enables to define patient groups that may benefit from GRPR targeted modalities. As a reference the androgen-independent xenograft model PC3 was used.
Although PC3 is androgen-independent, GRPR is constitutively overexpressed and, therefore, this model is frequently used in studies on GRPR expression in PC.
Materials and methods

PC Xenografts
For this study we made use of intact male nude NMRI (Naval Medical Research Institute) mice (Taconic M&B, Ry, Denmark) [15] [16] [17] March 1986).
Mice were implanted subcutaneously with small fragments of the androgendependent PC82, PC295 and PC310 human prostate tumour 15 . Mice were supplemented with testosterone to obtain optimal tumour take (80-85%) and tumour growth by implanting silastic tubings filled with crystalline steroid (6mg/tubing; AppliChem, Darmstadt, Germany). These implants result in constant delivery of testosterone exceeding the low physiological levels in intact male nude mice for at least 75 days 19 . For the androgen-independent PC3 xenografts, cell suspensions (5 million cells per mouse) were injected subcutaneously without additional testosterone supplementation. the Netherlands, DRN 4901, 370 MBq/ml in HCl, pH 1.5-1.9) as described earlier [21] [22] [23] [24] .
Androgen ablation and testosterone resupplementation
RNA isolation and quantitative reverse transcriptase polymerase chain reaction (RT-PCR)
For RT-PCR an independent set of PC82, PC295 and PC310 tumour tissue was obtained from our biorepository of xenograft tissues (snapfrozen material stored at minus 80°C) and not from tissues from the biodistribution studies as snapfrozen tissues are essential to obtain high quality RNA. Tumours from the biodistribution studies could only be frozen after counting in the gammacounter, which time delay strongly affects RNA quality.
Total RNA was isolated using RNAzol B kit (Bio-connect, Huissen, The Statistical analysis was performed using the unpaired 2-tailed t-test using SPSS 15.0 (SPSS Inc., Chicago, United States). A probability of less than 0.05 was considered significant.
Biodistribution Studies
For biodistribution studies, mice were injected intravenously with 4 MBq / 60 pmol (0. Statistical analysis was performed using the Mann Whitney and unpaired t-test.
A probability of less than 0.05 was considered significant.
Autoradiographic Analyses
PC xenograft tumour tissues derived from hormonally manipulated mice were evaluated for GRPR expression by in vitro autoradiography as described previously 17 . Statistical analysis was performed using the Mann Whitney and unpaired t-test.
Results
Effect of androgens on GRPR mRNA levels: Quantitative RT-PCR
To evaluate changes in mRNA expression of GRPR during androgen manipulation, RT-PCR was performed on RNA from an independent set of PC82, PC295 and PC310 tumour tissue obtained from our biorepository of xenograft tissues. In order to correct for variability of stromal (murine) content of the otherwise human (epithelial) tumours, human-specific probes were used and GRPR mRNA levels were related to GAPDH.
Relative GRPR mRNA levels under control conditions were high for PC295 and PC310
with a mean GRPR/GAPDH ratio of 27.2 and 21.5, respectively. PC82 showed much lower GRPR mRNA levels with a mean GRPR/GAPDH ratio of 4.1. After androgen ablation, the relative GRPR expression dropped considerably for PC295, PC310 and PC82 ( Figure 1 ). Re-supplementation with testosterone resulted in recovery of GRPR mRNA levels for all xenografts although recovery levels were quite variable ( Figure 1 ).
Effect of Androgens on GRPR-Mediated Tumour Uptake: Biodistribution Studies
Subsequent to the RT-PCR and initial autoradiography a prospective biodistribution study was performed to evaluate potential androgen regulation of GRPR and thus the effect of androgen status on GRPR-mediated tumour uptake in vivo using the radiolabelled BN analogue 111 In-MP2653 in PC tumour-bearing mice under hormonal manipulation. Table 1 summarizes the results of 3 independent biodistribution studies.
The first experiment was performed with the androgen dependent PC295 xenograft. The outcome of this study was further substantiated in a subsequent biodistribution study using the androgen sensitive xenograft PC82 with a more extended time point of testosterone re-supplementation. Finally, to validate the outcome of these 2 experiments, a third biodistribution study was performed with the androgen sensitive xenograft models PC295, PC82 and PC310, comparing GRPR expression in intact mice (control), castrated mice (cas 7), and castrated and re-supplemented mice (cas 7 T 14)
with the androgen-independent PC3 as reference model.
The uptake of the 111 In-labeled peptide at 4 hours after injection in the GRPRpositive tumour and GRPR-expressing pancreas as well as in the clearance organs (kidneys and intestines) were found to be in agreement with our previous results obtained with 111 In-MP2653 in mice bearing PC3 tumours 25 . Tumour and pancreas uptake in all PC xenografts are summarized in Table 1A . showing a decrease in tumour uptake of 73% (p = 0.0002) after 7 days of castration.
The reduction of peptide uptake in androgen depleted PC82 and PC310 tumours was less pronounced than in PC295, although still significant (54 % and 41% respectively after 7 days of castration, p < 0.017).
Re-supplementation of testosterone to castrated mice for 14 days resulted in near complete recovery of tumour uptake in PC82 and PC310 mice to control levels (86% and 99%, respectively). For PC295, a partial restoration (40%) of peptide uptake by the tumours was observed after 4 days of testosterone resupplementation.
Tumour growth of the androgen-independent PC3 model was not affected by ablation treatment nor by testosterone suppelmentation (data not shown). In contrast to the androgen sensitive xenografts, tumour uptake of 111 In-MP2653 was significantly increased up to 141% at 7 days post-castration, which was normalized after testosterone resupplementation.
111 In-MP2653 uptake in the GRPR expressing pancreas was similar for all mice under the various hormonal conditions ( Table 1) .
Effect of Androgens on GRPR-mediated binding: Autoradiographic Analyses
The effect of androgen status on GRPR-mediated binding in human PC was evaluated in vitro by autoradiography. Initially, autoradiographic analysis was performed on tumour sections derived from our biorepository of xenograft tissues (snapfrozen material stored at minus 80°C) using 125 I-universal-BN (74 TBq/mmol). This tumour collection contained tissues from control mice, castrated mice (castrated 8-10 days prior to sacrifice) and castrated mice that were resupplemented with testosterone for indicated days (see Figure 2) . Binding of 125 I-universal-BN was drastically reduced after androgen ablation in all 3 androgen-dependent PC xenografts resulting in 95%, 77% and 90% reduced binding in PC295, PC310, and PC82, respectively. Testosterone resupplementation partially restored binding to 70% and 54% of control level as observed for PC295 and PC82, respectively, while such restoration of peptide binding was not observed for PC310 after 13 days of testosterone administration (Figure 2 ).
Additional autoradiographic evaluations were performed on tumour sections derived from the prospective biodistribution studies using 125 I-GRP (74 TBq/mmol) or 
Discussion
Opportunistic screening for PC has led to diagnosis of more PC tumours still confined to the prostate in which curative surgical intervention is still an option. However, due to lack of accurate imaging modalities for PC, the (micro)metastatic stage of the tumour is often difficult to determine. The metastatic stage of PC greatly influences prognosis and determines therapeutic options of the disease. Therefore, reliable and sensitive diagnostic tools are highly wanted to improve staging at time of diagnosis.
Radiolabelled BN analogues may be promising new radiopharmaceuticals for imaging and therapy for patients with GRPR-expressing tumours, such as PC [26] [27] [28] [29] [30] [31] .
Evaluation of GRPR expression throughout the different stages of human prostate tumour development using a panel of 12 well established human PC xenograft models has shown that GRPRs were predominantly expressed in androgen-dependent xenografts and were very low in androgen-independent xenografts 17 . This observation stimulated further research into the potential effects of androgen status on the expression of the GRPR in PC patients and, consequently, the relevance of their clinical history (therapy sequence). To further study androgen regulation of the GRPR we used three androgenresponsive prostate cancer models. We hypothesized that if GRPR-expression was indeed regulated by androgens, androgen ablation of androgen-dependent xenograft bearing mice would reduce GRPR expression and recovery of androgen status would induce reappearance of GRPR expression. An initial in vitro autoradiographic binding study using RT-PCR study than showed that after ablation of androgens GRPR mRNA expression was significantly reduced in all androgen-dependent tumour types while restoration of relative GRPR mRNA levels was achieved after androgen resupplementation. Variability in recovery of GRPR may be related to differences in the kinetics of the process of GRPR translation from mRNA to protein and reappearance.
These results supported our hypothesis that in androgen-dependent xenografts representing early stage of PC, transcription of GRPR mRNA is androgen regulated.
Subsequent in vivo biodistribution studies were performed with the previously evaluated 111 In-MP2653 analogue 25 . Consistent with the autoradiographic results, 111 In- Consequently tumours in such xenografts will contain less (human) epithelial cells as compared to the (non androgen responsive) stromal compartment. It was essential to verify whether the observed effects were caused by regulation of GRPR expression itself or by changes in the total epithelial (human) content of the xenograft. RT-PCR enables to correct for these changes while expression of GRPR mRNA was related to GAPDH mRNA expression levels using human-specific primer probe sets for both GRPR and GAPDH hereby excluding the non human stromal compartment.
Although none of our xenograft models representing late stage disease expressed GRPR 35 , it cannot be excluded that GRPR may be re-expressed in progressive, late stage disease as has been suggested from patient samples 5 and few patients in clinical studies 31 .
Conclusion
GRPR-binding of androgen-dependent human PC xenograft models is androgen- Legends Table 1 Results of biodistribution and in vitro autoradiographic studies.
A Biodistribution results are average tumour and pancreas uptake of 
